MCID: SKN013
MIFTS: 51

Skin Benign Neoplasm

Categories: Cancer diseases, Skin diseases

Aliases & Classifications for Skin Benign Neoplasm

MalaCards integrated aliases for Skin Benign Neoplasm:

Name: Skin Benign Neoplasm 12 15
Neoplasm of Skin by Site 12
Benign Neoplasm of Skin 71
Tumor of the Skin 12
Skin Neoplasms 71
Skin Tumor 54

Classifications:



External Ids:

Disease Ontology 12 DOID:3165
MeSH 43 D012878
NCIt 49 C3372
SNOMED-CT 67 126488004
ICD10 32 D23.9
UMLS 71 C0004998 C0037286

Summaries for Skin Benign Neoplasm

MalaCards based summary : Skin Benign Neoplasm, also known as neoplasm of skin by site, is related to muir-torre syndrome and melanocytic nevus syndrome, congenital, and has symptoms including pruritus and exanthema. An important gene associated with Skin Benign Neoplasm is KRT14 (Keratin 14), and among its related pathways/superpathways are Developmental Biology and G-Beta Gamma Signaling. The drugs Etanercept and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and t cells, and related phenotypes are cellular and growth/size/body region

Related Diseases for Skin Benign Neoplasm

Diseases related to Skin Benign Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 521)
# Related Disease Score Top Affiliating Genes
1 muir-torre syndrome 32.7 MSH6 MSH2 MLH1
2 melanocytic nevus syndrome, congenital 32.4 MSH2 MLH1 HRAS
3 neurofibromatosis, type i 32.3 MSH6 MSH2 MLH1 HRAS
4 mismatch repair cancer syndrome 32.2 MSH6 MSH2 MLH1
5 lynch syndrome i 32.2 MSH6 MSH2 MLH1
6 nevus, epidermal 31.2 KRT1 HRAS FGFR3
7 sebaceous adenocarcinoma 30.8 MSH6 MSH2 MLH1 KRT5 KRT14
8 fibroma 30.7 SERPINA3 PTCH1 KRT14
9 skin papilloma 30.6 ODC1 KRT14 KRT1 JUN HRAS
10 in situ carcinoma 30.6 SERPINA3 KRT5 KRT14 HRAS
11 adenoma 30.6 ODC1 MSH6 MSH2 MLH1 KRT20
12 sebaceous adenoma 30.5 SERPINA3 MSH6 MSH2 MLH1
13 keratoacanthoma 30.5 MSH2 MLH1 KRT14
14 neurofibromatosis 30.5 MSH6 MSH2 MLH1 HRAS
15 eccrine porocarcinoma 30.5 STAT3 KRT5 KRT1
16 dysplastic nevus syndrome 30.4 MSH6 MSH2 MLH1
17 keratosis 30.4 KRT5 KRT1 HRAS FGFR3
18 eccrine acrospiroma 30.3 KRT5 KRT14
19 spindle cell carcinoma 30.3 TP63 KRT5 KRT14 HRAS
20 actinic keratosis 30.3 TP63 KRT20 HRAS
21 squamous cell papilloma 30.2 KRT14 HRAS
22 basal cell nevus syndrome 30.2 XPA PTCH1 GLI2 GLI1
23 familial adenomatous polyposis 30.1 ODC1 MSH6 MSH2 MLH1 HRAS
24 myeloma, multiple 30.1 STAT3 SERPINA3 JUN HRAS FGFR3
25 basal cell carcinoma 30.1 XPA TP63 STAT3 PTCH1 KRT5 KRT20
26 cystic basal cell carcinoma 30.1 TP63 PTCH1 KRT5 KRT20 KRT14
27 cheilitis 30.1 STAT3 MSH2 FGFR3
28 polycystic liver disease 1 with or without kidney cysts 30.0 PTCH1 KRT20 KRT13 FLCN
29 melanoma, cutaneous malignant 1 30.0 XPA MSH6 MSH2 MLH1 HRAS
30 colorectal adenoma 30.0 ODC1 MSH2 MLH1 HRAS
31 xeroderma pigmentosum, variant type 30.0 XPA PTCH1 MSH6 MSH2 MLH1
32 lynch syndrome 30.0 MSH6 MSH2 MLH1 HRAS
33 skin squamous cell carcinoma 29.9 MSH6 MSH2 MLH1 KRT5 KRT14 KRT1
34 lymphangioma 29.9 STAT3 SERPINA3 MSH2 MLH1 HRAS
35 squamous cell carcinoma 29.9 TP63 STAT3 PTCH1 KRT14 KRT13 HRAS
36 sarcoma 29.9 STAT3 SERPINA3 MSH2 JUN HRAS FGFR3
37 cowden syndrome 29.8 MSH6 MSH2 MLH1 HRAS FLCN
38 rhabdomyosarcoma 29.8 PTCH1 MSH6 MSH2 HRAS GLI1
39 skin disease 29.8 TP63 SERPINA3 KRT5 KRT14 KRT1 FGFR3
40 skin carcinoma 29.7 XPA PTCH1 ODC1 MSH2 KRT20 JUN
41 hematologic cancer 29.7 STAT3 SERPINA3 MSH2 MLH1 HRAS
42 aging 29.6 TP63 STAT3 JUN
43 adenocarcinoma 29.6 STAT3 MSH6 MSH2 MLH1 KRT20 HRAS
44 adenoid cystic carcinoma 29.6 TP63 STAT3 SERPINA3 KRT5 KRT20 KRT14
45 bladder cancer 29.5 TP63 STAT3 PTCH1 MLH1 KRT20 HRAS
46 brain cancer 29.4 STAT3 SERPINA3 PTCH1 MSH6 MSH2 HRAS
47 neuroblastoma 29.4 STAT3 PTCH1 ODC1 MSH2 KRT1 JUN
48 cervical cancer 29.3 TP63 STAT3 MLH1 KRT14 JUN HRAS
49 esophageal cancer 29.2 TP63 STAT3 MSH2 MLH1 JUN HRAS
50 papilloma 29.2 TP63 ODC1 KRT5 KRT20 KRT14 KRT13

Graphical network of the top 20 diseases related to Skin Benign Neoplasm:



Diseases related to Skin Benign Neoplasm

Symptoms & Phenotypes for Skin Benign Neoplasm

UMLS symptoms related to Skin Benign Neoplasm:


pruritus, exanthema

MGI Mouse Phenotypes related to Skin Benign Neoplasm:

45 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.4 FGFR3 FLCN GLI1 GLI2 JUN KRT14
2 growth/size/body region MP:0005378 10.36 FGFR3 FLCN GLI1 GLI2 HRAS JUN
3 behavior/neurological MP:0005386 10.35 FGFR3 GLI1 GLI2 HRAS JUN KRT5
4 homeostasis/metabolism MP:0005376 10.35 FGFR3 FLCN GLI2 HRAS JUN KRT1
5 integument MP:0010771 10.31 FGFR3 GLI2 HRAS JUN KRT1 KRT14
6 mortality/aging MP:0010768 10.3 FGFR3 FLCN GLI1 GLI2 HRAS JUN
7 digestive/alimentary MP:0005381 10.28 FGFR3 GLI1 GLI2 HRAS KRT14 KRT5
8 craniofacial MP:0005382 10.25 FGFR3 GLI1 GLI2 HRAS KRT14 KRT5
9 hematopoietic system MP:0005397 10.24 FGFR3 FLCN JUN KRT1 KRT14 MLH1
10 immune system MP:0005387 10.23 FGFR3 FLCN JUN KRT1 KRT14 MLH1
11 endocrine/exocrine gland MP:0005379 10.22 GLI1 GLI2 HRAS JUN KRT14 MLH1
12 neoplasm MP:0002006 10.1 FGFR3 FLCN GLI1 HRAS KRT14 MLH1
13 limbs/digits/tail MP:0005371 9.95 FGFR3 GLI1 GLI2 KRT5 PTCH1 TP63
14 normal MP:0002873 9.81 FGFR3 GLI1 GLI2 HRAS JUN ODC1
15 no phenotypic analysis MP:0003012 9.8 FGFR3 GLI1 GLI2 HRAS JUN PTCH1
16 respiratory system MP:0005388 9.7 FGFR3 GLI1 GLI2 HRAS JUN KRT14
17 vision/eye MP:0005391 9.28 FGFR3 GLI2 JUN KRT14 MLH1 PTCH1

Drugs & Therapeutics for Skin Benign Neoplasm

Drugs for Skin Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 296)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etanercept Approved, Investigational Phase 4 185243-69-0
2
Fluorouracil Approved Phase 4 51-21-8 3385
3
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
4
Bacitracin Approved, Vet_approved Phase 4 1405-87-4 439542 10909430
5
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560 441411
6
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
7
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
8
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
9
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
10
Mycophenolic acid Approved Phase 4 24280-93-1 446541
11
Azathioprine Approved Phase 4 446-86-6 2265
12
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
13 Triamcinolone diacetate Phase 4
14 triamcinolone acetonide Phase 4
15 Triamcinolone hexacetonide Phase 4
16 Tin Fluorides Phase 4
17 Anti-Infective Agents, Local Phase 4
18 Erythromycin Estolate Phase 4
19 Erythromycin stearate Phase 4
20 Lubricant Eye Drops Phase 4
21 Erythromycin Ethylsuccinate Phase 4
22 Dermatologic Agents Phase 4
23 Antifungal Agents Phase 4
24 Cyclosporins Phase 4
25 Calcineurin Inhibitors Phase 4
26 Antimetabolites Phase 4
27 Neurotransmitter Agents Phase 4
28 Agglutinins Phase 4
29 abobotulinumtoxinA Phase 4
30 Cholinergic Agents Phase 4
31 Hemagglutinins Phase 4
32 Botulinum Toxins Phase 4
33 Botulinum Toxins, Type A Phase 4
34
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
35
Acetaminophen Approved Phase 3 103-90-2 1983
36
Vinblastine Approved Phase 3 865-21-4 241903 13342
37
Sorafenib Approved, Investigational Phase 3 284461-73-0 216239 406563
38
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
39
nivolumab Approved Phase 3 946414-94-4
40
Dabrafenib Approved, Investigational Phase 3 1195765-45-7 44462760 44516822
41
Trametinib Approved Phase 3 871700-17-3 11707110
42
Dimethyl sulfoxide Approved, Vet_approved Phase 3 67-68-5 679
43
Ipilimumab Approved Phase 3 477202-00-9
44
Vemurafenib Approved Phase 3 918504-65-1 23252090 42611257
45
Talimogene laherparepvec Approved, Experimental, Investigational Phase 3 1187560-31-1
46
Temozolomide Approved, Investigational Phase 3 85622-93-1 5394
47
Dacarbazine Approved, Investigational Phase 3 4342-03-4 5351166
48
Ornithine Approved, Nutraceutical Phase 3 70-26-8, 3184-13-2 6262
49
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 444795 5538
50
Vitamin D3 Approved, Nutraceutical Phase 3 67-97-0 5280795 6221

Interventional clinical trials:

(show top 50) (show all 484)
# Name Status NCT ID Phase Drugs
1 A Randomized, Open-Label Study to Compare the Rate of New Non-Melanoma Skin Cancer in Maintenance Renal Allograft Recipients Converted to a Sirolimus-based Regimen Versus Continuation of a Calcineurin Inhibitor-based Regimen Completed NCT00129961 Phase 4 sirolimus;cyclosporine or tacrolimus
2 Photosensitivity of the Skin Under Azathioprin in Renal Transplant Recipients Completed NCT00492895 Phase 4 Discontinuation of Azathioprin
3 Can We Miss Pigmented Lesions in Psoriasis Patients? Completed NCT01053819 Phase 4 etanercept
4 CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial Completed NCT00847912 Phase 4 5-fluorouracil;Placebo, vehicle control
5 Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma: a Single Arm Prospective Study Recruiting NCT04056962 Phase 4 Tacrolimus ointment
6 The Role of Topical Antibiotic Prophylaxis in Eyelid Surgery Recruiting NCT03199911 Phase 4 Topical Anti-Infective Product;Topical Ointment
7 Efficacy of Rapamycin (Sirolimus) in the Treatment of Blue Rubber Bleb Nevus Syndrome, Hereditary or Sporadic Venous Malformation Recruiting NCT03767660 Phase 4 Rapamycin
8 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT01797315 Phase 4 Sirolimus
9 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT00866684 Phase 4 Sirolimus;Azathioprine;Mycophenolate;Ciclosporin;Tacrolimus
10 A Prospective, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of AbobotulinumtoxinA (BTX-A) in Improving Forehead Wounds After Mohs Micrographic Surgery and Reconstruction for Skin Cancer Terminated NCT01459666 Phase 4 Dysport (abobotulinumtoxinA);Bacteriostatic 0.9% Sodium Chloride (vehicle)
11 CERTICOEUR a Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. An Open Labelled Randomized Everolimus vs Calcineurin Inhibitors Multicenter Trial Unknown status NCT00799188 Phase 3 Everolimus
12 Prospective and Randomized Study to Evaluate Interest of Ultracision Use in Inguinal Lymph Nodes Curage. Completed NCT00224744 Phase 3
13 Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients - Multicentric Randomized, Open-label Study of Rapamycin vs Calcineurin Inhibitors Completed NCT00133887 Phase 3 rapamycin;ciclosporine;tacrolimus
14 Impact of Preoperative Acetaminophen and Carbohydrate Loading to on Pain and Functional Status in Patients Undergoing Mohs Micrographic Surgery for Non-melanoma Skin Cancers Completed NCT03131713 Phase 3 Acetaminophen
15 Phase III Randomized Study of Dacarbazine With or Without Allovectin-7 in Patients With Metastatic Melanoma Completed NCT00003647 Phase 3 allovectin-7;allovectin-7/dacarbazine;dacarbazine
16 Prospective Study To Determine Whether Tissue Scoring Results In Noticeable Marks Following Mohs Micrographic Surgery Completed NCT00367042 Phase 2, Phase 3
17 A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma Completed NCT01763164 Phase 3 MEK162;Dacarbazine
18 Chemoprevention of Skin Cancers With DFMO: A Controlled, Randomized Clinical Trial Completed NCT00005884 Phase 3 eflornithine
19 A Randomized Controlled Trial of Excisional Surgery Versus Imiquimod 5% Cream for Nodular and Superficial Basal Cell Carcinoma Completed NCT00066872 Phase 3 imiquimod
20 A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma Completed NCT00110019 Phase 3 Carboplatin;Paclitaxel;Sorafenib Tosylate
21 A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma Completed NCT00019682 Phase 3 Montanide ISA 51 VG
22 A Randomized Control Trial of Sun Protection Interventions for Operating Engineers Completed NCT01804595 Phase 2, Phase 3
23 A Multicentre, Randomised Study of Photodynamic Therapy(PDT) With Metvix® 160 mg/g Cream in Immuno-compromised Patients With Non-melanoma Skin Cancer Completed NCT00472459 Phase 3
24 CSP #402 - VA Topical Tretinoin Chemoprevention Trial Completed NCT00007631 Phase 3 Tretinoin 0.1% cream or placebo
25 Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy in High-risk Cutaneous Squamous Cell Carcinoma of the Head and Neck Completed NCT00193895 Phase 3 Carboplatin
26 A Randomized Controlled Trial Of CHARTWEL (a Continuous Hyperfractionated Accelerated Radiotherapy Schedule) Versus Conventional Radiotherapy In Post-Operative Head And Neck Cancer Patients Completed NCT00021125 Phase 3
27 Adjuvant Therapy for Melanoma Patients With Regional Lymph Node Metastases With Interferon Alfa-2B vs. Biochemotherapy Using Cisplatin + Vinblastine + DTIC + Interferon Plus IL-2 Completed NCT00002882 Phase 3 Cisplatin;Dacarbazine;Vinblastine
28 A Randomized, Placebo-Controlled Phase III Trial of Yeast Derived GM-CSF Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With "No Evidence of Disease" After Complete Surgical Resection of "Locally Advanced" and/or Stage IV Melanoma Completed NCT01989572 Phase 3
29 Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome Recruiting NCT01748448 Phase 3 Vitamin D;arachides oleum raffinatum
30 Melanoma Margins Trial-II - A Phase III, Multi-centre Randomised Controlled Trial Investigating 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma (ANZMTG 02.18 MelMarT-II) Recruiting NCT03860883 Phase 3
31 A Personalized Approach to Skin Cancer Prevention Among Adolescents Recruiting NCT04341064 Phase 3
32 DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial Recruiting NCT02224781 Phase 3 Dabrafenib;Dabrafenib Mesylate;Trametinib;Trametinib Dimethyl Sulfoxide
33 A Phase 3, Randomized, Double-blind Study of BMS-986205 Combined With Nivolumab Versus Nivolumab in Participants With Metastatic or Unresectable Melanoma That is Previously Untreated Active, not recruiting NCT03329846 Phase 3 BMS-986205;Placebo
34 A 2-part Phase III Randomized, Open Label, Multicenter Study of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma Active, not recruiting NCT01909453 Phase 3 LGX818;MEK162;vemurafenib
35 A Phase III, Multi-centre, Multi-national Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma Active, not recruiting NCT02385214 Phase 3
36 A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma Active, not recruiting NCT01274338 Phase 3
37 A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma Active, not recruiting NCT02506153 Phase 3
38 Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma Suspended NCT02339571 Phase 2, Phase 3
39 PV-10 Intralesional Injection vs Systemic Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma Terminated NCT02288897 Phase 3 PV-10 (10% rose bengal disodium);Dacarbazine, temozolomide or talimogene laherparepvec
40 Transient Infrared Imaging for Early Detection of Skin Cancer Unknown status NCT02154451 Phase 1, Phase 2
41 Skin Cancer Prophylaxis by Low-Fat Dietary Intervention Unknown status NCT00003097 Phase 2
42 Investigation of the Effectiveness of Non-Coherent Blue Light in Intralesional Photodynamic of Basal Cell Carcinoma Unknown status NCT00747903 Phase 2 aminolevulinic acid hydrochloride
43 A Phase 2, Open-Label Evaluation of the Safety and Efficacy of CB-10-01, Transgenic Lymphocyte Immunization (TLI) Against Telomerase, as Adjuvant Therapy in Subjects With Stage III Melanoma Unknown status NCT00925314 Phase 2
44 A Phase I/II Pilot Study of Bioimmunotherapy With IRESSA (Gefitinib) and Pegylated Interferon Alpha-2a for Patients With Unresectable/Metastatic Squamous Cell Carcinoma of the Skin Unknown status NCT00423397 Phase 1, Phase 2 gefitinib
45 Phase IIB Study to Evaluate the Safety and Efficacy of Topical Difluoromethylornithine and Topical Diclofenac in the Treatment of Sun-Damaged Skin on the Forearm Completed NCT00601640 Phase 2 Diclofenac Na gel;Eflornithine HCL ointment
46 Study of Talabostat in Advanced Melanoma Completed NCT00083239 Phase 2 talabostat (PT-100) tablets
47 Study of Talabostat and Cisplatin in Advanced Melanoma Completed NCT00083252 Phase 2 talabostat (PT-100) tablets;cisplatin
48 Pilot Phase II, Open Label, Multicenter, Efficacy and Safety Study of 852A Administered Intravenously to Subjects With Unresectable Metastatic Cutaneous Melanoma. Completed NCT00189332 Phase 2 852A
49 A Phase II Safety and Activity Study of Ritonavir in the Treatment of HIV-Associated Cutaneous Kaposi's Sarcoma Completed NCT00002366 Phase 2 Ritonavir
50 A Phase II Randomized, Open-label Study Investigating the Healing Effects of HP802-247 Versus Antibiotic Ointment in Mohs Micrographic Surgery Patients Completed NCT01359735 Phase 2

Search NIH Clinical Center for Skin Benign Neoplasm

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cholecalciferol
Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
peginterferon alfa-2a
peginterferon alfa-2b
Recombinant interferon beta-1a
Recombinant interferon beta-1b

Genetic Tests for Skin Benign Neoplasm

Anatomical Context for Skin Benign Neoplasm

MalaCards organs/tissues related to Skin Benign Neoplasm:

40
Skin, Testes, T Cells, Lymph Node, Lung, Breast, Brain

Publications for Skin Benign Neoplasm

Articles related to Skin Benign Neoplasm:

(show top 50) (show all 459)
# Title Authors PMID Year
1
Giant Mixed Tumor of the Skin Affecting the Hemiface. 61
32516219 2020
2
Cutaneous Adenosquamous Carcinoma of the Scalp With Intestinal Phenotype. 61
32379088 2020
3
Histopathological Study of Skin Lesions in a Tertiary Care Hospital: A Descriptive Cross-sectional Study. 61
32417857 2020
4
Unmasking dermatofibrosarcoma protuberans: Case report of an atypical presentation complicated by post-surgical excision. 61
32305027 2020
5
Soft tissue sarcoma in neurofibromatosis type 1: A rare case of malignant peripheral nerve sheath tumor of the skin. 61
31964130 2020
6
Mixed Tumor of the Nasal Root. 61
32537304 2019
7
Lobular capillary hemangioma in a patient with ankylosing spondylitis using adalimumab: an exuberant presentation. 61
31789263 2019
8
Meningioma-like Tumor of the Skin Revisited: A Distinct CD34+ Dermal Tumor With an Expanded Histologic Spectrum. 61
31490235 2019
9
Fibroblast growth factor receptor promotes progression of cutaneous squamous cell carcinoma. 61
31254372 2019
10
[Erratum to: Malignant collision tumor of the skin : Melanoma, squamous cell carcinoma and basal cell carcinoma]. 61
31312888 2019
11
Common Nevus and Skin Cutaneous Melanoma: Prognostic Genes Identified by Gene Co-Expression Network Analysis. 61
31557882 2019
12
[Malignant collision tumor of the skin : Melanoma, squamous cell carcinoma and basal cell carcinoma]. 61
31168637 2019
13
Fine-needle aspiration of dermatofibrosarcoma protuberans metastasizing to hemithorax with superior vena cava compression: Case report and literature review. 61
30919592 2019
14
Merkel Cell Carcinoma of the Digit. 61
31008795 2019
15
Nasal flap or cutaneous grafting in basal cell cancer of the nose. Comparison of two reconstructive possibilities. 61
32011980 2019
16
Trichofolliculoma of the Eyelid Margin: A Case Report and Review of Literature. 61
30908463 2019
17
Primary Cutaneous Neuroendocrine Carcinoma with Diffuse Expression of Thyroid Transcription Factor-1: Report of Two Cases. 61
31148874 2019
18
Facial distribution of squamous cell carcinoma in Japanese. 61
30698883 2019
19
Malignant Sweat Gland Tumors. 61
30497677 2019
20
[Head & Neck Merkel Cell Carcinoma]. 61
30005427 2019
21
Angiolymphoid hyperplasia with eosinophilia with clinical pictures of keratoacanthoma: A rare case report. 61
30656039 2019
22
Recurrent Merkel cell carcinoma of the gluteal region: A case report. 61
30238578 2019
23
MiR-203 regulates keloid fibroblast proliferation, invasion, and extracellular matrix expression by targeting EGR1 and FGF2. 61
30372829 2018
24
A Case Report of Recurrent Metastatic Sebaceous Carcinoma Which Showed Favorable Response Tt Non-Fluorouracil Based Chemotherapy. 61
30291222 2018
25
The Ashitaba (Angelica keiskei) Chalcones 4-hydroxyderricin and Xanthoangelol Suppress Melanomagenesis By Targeting BRAF and PI3K. 61
29980517 2018
26
Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches. 61
30073632 2018
27
Benign chondroid syringoma affecting the upper lip: Report of a rare case and review of literature. 61
30651687 2018
28
Clinical and pathological study on mixed tumors of the skin. 61
30200138 2018
29
Recurrent Indeterminate Dendritic Cell Tumor of the Skin. 61
29621879 2018
30
A rare case of hyaline cell-rich atypical chondroid syringoma with divergent differentiation. 61
30004073 2018
31
[Clinicopathologic characterization of malignant mixed tumor of the skin accompanied by eccrine porocarcinoma]. 61
29996320 2018
32
Merkel cell carcinoma in the community setting: a case report. 61
29627970 2018
33
Merkel Cell Carcinoma in the Age of Immunotherapy: Facts and Hopes. 61
29217527 2018
34
Merkel cell carcinomas infiltrated with CD33+ myeloid cells and CD8+ T cells are associated with improved outcome. 61
29273486 2018
35
Microcystic adnexal carcinoma with sebaceous differentiation: Three cases. 61
29352496 2018
36
Merkel cell carcinoma: An update and review: Current and future therapy. 61
29229573 2018
37
Asymptomatic flesh-colored lobular nodule on the nose. 61
29630154 2018
38
Basal Cell Carcinoma with Myoepithelial Differentiation: Case Report and Literature Review. 61
29560294 2018
39
Merkel cell carcinoma of the eyelid and orbit. 61
30541295 2018
40
Bioinformatics analysis of gene expression alterations conferring drug resistance in tumor samples from melanoma patients with EGFR-activating BRAF mutations. 61
29387237 2018
41
Efficacy of isolated limb perfusion (ILP) in patients with Merkel cell carcinoma (MCC): A multicenter experience. 61
28802661 2017
42
Tumor vascularization and clinicopathologic parameters as prognostic factors in merkel cell carcinoma. 61
28639083 2017
43
Blastic plasmacytoid dendritic cell neoplasm in children: A review of two cases. 61
28856005 2017
44
Age and Gender Associations of Virus Positivity in Merkel Cell Carcinoma Characterized Using a Novel RNA In Situ Hybridization Assay. 61
28606924 2017
45
Avelumab for the treatment of metastatic Merkel cell carcinoma. 61
28837181 2017
46
Papillary endothelial hyperplasia (Masson's tumor) in children. 61
27346753 2017
47
Primary cutaneous sarcomatoid carcinoma presenting as a rapidly-growing and ulcerative tumor of the skin. 61
28601237 2017
48
Effect of melanoma cells on proliferation and migration of activated hepatic stellate cells in vitro. 61
28279493 2017
49
[Malignant transformation of an eccrine spiradenoma]. 61
28277254 2017
50
[Merkel cell carcinoma of the eyelid. An often unrecognized tumor entity : Clinical aspects and treatment strategies]. 61
27651329 2017

Variations for Skin Benign Neoplasm

Expression for Skin Benign Neoplasm

Search GEO for disease gene expression data for Skin Benign Neoplasm.

Pathways for Skin Benign Neoplasm

Pathways related to Skin Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 31)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.27 STAT3 KRT5 KRT20 KRT14 KRT13 KRT1
2
Show member pathways
12.98 PTCH1 KRT1 JUN HRAS GLI2 GLI1
3
Show member pathways
12.85 STAT3 MSH6 MSH2 MLH1 JUN HRAS
4
Show member pathways
12.75 STAT3 MSH6 MSH2 MLH1 JUN HRAS
5
Show member pathways
12.56 STAT3 JUN HRAS FLCN FGFR3
6 12.38 XPA TP63 MSH6 MSH2 MLH1
7
Show member pathways
12.33 KRT5 KRT20 KRT14 KRT13 KRT1
8
Show member pathways
12.33 STAT3 KRT20 KRT14 KRT13 JUN HRAS
9 12.13 STAT3 MSH6 MSH2 MLH1
10
Show member pathways
12.09 STAT3 PTCH1 HRAS GLI2 GLI1
11 12.08 ODC1 MSH6 MSH2 JUN
12 12.05 STAT3 PTCH1 MSH6 MSH2 MLH1 JUN
13 11.96 TP63 MSH2 MLH1 JUN
14 11.81 KRT20 KRT14 KRT13
15
Show member pathways
11.8 MSH6 MSH2 MLH1
16
Show member pathways
11.77 KRT5 KRT14 KRT13 KRT1
17 11.73 KRT5 KRT14 JUN
18 11.64 STAT3 JUN HRAS
19 11.56 STAT3 JUN HRAS
20 11.49 PTCH1 GLI2 GLI1
21 11.4 PTCH1 GLI2 GLI1
22
Show member pathways
11.4 STAT3 MSH2 MLH1
23 11.38 JUN HRAS FGFR3
24 11.32 PTCH1 GLI2 GLI1
25 11.32 XPA MSH6 MSH2 MLH1
26 11.3 STAT3 JUN HRAS
27 11.19 STAT3 JUN HRAS
28 11.11 STAT3 GLI2 GLI1
29
Show member pathways
10.78 PTCH1 GLI2 GLI1
30 10.76 STAT3 JUN
31 10.72 XPA MSH6 MSH2 MLH1

GO Terms for Skin Benign Neoplasm

Cellular components related to Skin Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 10.18 STAT3 ODC1 MSH6 KRT5 KRT20 KRT14
2 nucleus GO:0005634 9.58 XPA TP63 STAT3 SERPINA3 PTCH1 MSH6
3 keratin filament GO:0045095 9.56 KRT5 KRT14 KRT13 KRT1
4 intermediate filament GO:0005882 9.55 KRT5 KRT20 KRT14 KRT13 KRT1
5 MutSalpha complex GO:0032301 9.32 MSH6 MSH2
6 mismatch repair complex GO:0032300 9.13 MSH6 MSH2 MLH1

Biological processes related to Skin Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.18 TP63 STAT3 JUN HRAS GLI2 GLI1
2 negative regulation of transcription by RNA polymerase II GO:0000122 10.14 TP63 STAT3 PTCH1 JUN GLI2 FLCN
3 positive regulation of transcription, DNA-templated GO:0045893 10.07 TP63 STAT3 PTCH1 JUN GLI2 GLI1
4 in utero embryonic development GO:0001701 9.95 PTCH1 MSH2 GLI2 FLCN
5 aging GO:0007568 9.92 TP63 STAT3 KRT14 JUN
6 positive regulation of cell proliferation GO:0008284 9.87 STAT3 ODC1 JUN HRAS GLI2 GLI1
7 keratinization GO:0031424 9.85 KRT5 KRT20 KRT14 KRT13 KRT1
8 epidermis development GO:0008544 9.83 TP63 PTCH1 KRT5 KRT14
9 smoothened signaling pathway GO:0007224 9.82 PTCH1 GLI2 GLI1
10 pattern specification process GO:0007389 9.8 TP63 PTCH1 GLI2
11 dorsal/ventral pattern formation GO:0009953 9.76 PTCH1 GLI2 GLI1
12 mismatch repair GO:0006298 9.71 MSH6 MSH2 MLH1
13 proximal/distal pattern formation GO:0009954 9.69 TP63 GLI2 GLI1
14 dorsal/ventral neural tube patterning GO:0021904 9.67 PTCH1 GLI2
15 hemidesmosome assembly GO:0031581 9.66 KRT5 KRT14
16 positive regulation of isotype switching to IgG isotypes GO:0048304 9.65 MSH2 MLH1
17 epidermal cell differentiation GO:0009913 9.65 TP63 GLI1
18 smoothened signaling pathway involved in dorsal/ventral neural tube patterning GO:0060831 9.63 PTCH1 GLI2
19 mammary gland duct morphogenesis GO:0060603 9.62 PTCH1 GLI2
20 positive regulation of helicase activity GO:0051096 9.61 MSH6 MSH2
21 positive regulation of isotype switching to IgA isotypes GO:0048298 9.61 MSH2 MLH1
22 isotype switching GO:0045190 9.61 MSH6 MSH2 MLH1
23 maintenance of DNA repeat elements GO:0043570 9.6 MSH6 MSH2
24 prostatic bud formation GO:0060513 9.58 TP63 GLI2
25 somatic hypermutation of immunoglobulin genes GO:0016446 9.58 MSH6 MSH2 MLH1
26 smoothened signaling pathway involved in regulation of cerebellar granule cell precursor cell proliferation GO:0021938 9.57 GLI2 GLI1
27 cerebellar cortex morphogenesis GO:0021696 9.56 GLI2 GLI1
28 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.56 XPA MSH6 MSH2 MLH1
29 ventral midline development GO:0007418 9.55 GLI2 GLI1
30 cornification GO:0070268 9.55 KRT5 KRT20 KRT14 KRT13 KRT1
31 prostate gland development GO:0030850 9.54 TP63 PTCH1 GLI1
32 notochord regression GO:0060032 9.49 GLI2 GLI1
33 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 9.48 MSH2 MLH1
34 positive regulation of DNA replication GO:0045740 9.26 JUN HRAS GLI2 GLI1
35 somatic recombination of immunoglobulin gene segments GO:0016447 8.8 MSH6 MSH2 MLH1

Molecular functions related to Skin Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 10.16 XPA TP63 STAT3 SERPINA3 MSH6 MSH2
2 protein binding GO:0005515 9.96 XPA TP63 STAT3 SERPINA3 PTCH1 ODC1
3 transcription regulatory region DNA binding GO:0044212 9.77 TP63 STAT3 JUN GLI2 GLI1
4 double-stranded DNA binding GO:0003690 9.76 TP63 MSH6 MSH2 JUN
5 chromatin binding GO:0003682 9.7 TP63 MSH6 MSH2 MLH1 JUN GLI2
6 damaged DNA binding GO:0003684 9.62 XPA TP63 MSH6 MSH2
7 MutLalpha complex binding GO:0032405 9.49 MSH6 MSH2
8 oxidized purine DNA binding GO:0032357 9.48 MSH6 MSH2
9 single guanine insertion binding GO:0032142 9.43 MSH6 MSH2
10 mismatched DNA binding GO:0030983 9.43 MSH6 MSH2 MLH1
11 single thymine insertion binding GO:0032143 9.4 MSH6 MSH2
12 guanine/thymine mispair binding GO:0032137 8.8 MSH6 MSH2 MLH1

Sources for Skin Benign Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....